Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Celldex Therapeutics (CLDX) EBT (2016 - 2025)

Historic EBT for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to -$67.0 million.

  • Celldex Therapeutics' EBT fell 5917.0% to -$67.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$224.5 million, marking a year-over-year decrease of 4572.71%. This contributed to the annual value of -$157.9 million for FY2024, which is 1162.0% down from last year.
  • Latest data reveals that Celldex Therapeutics reported EBT of -$67.0 million as of Q3 2025, which was down 5917.0% from -$56.6 million recorded in Q2 2025.
  • Celldex Therapeutics' 5-year EBT high stood at -$13.4 million for Q2 2021, and its period low was -$67.0 million during Q3 2025.
  • Moreover, its 5-year median value for EBT was -$32.8 million (2024), whereas its average is -$34.7 million.
  • In the last 5 years, Celldex Therapeutics' EBT crashed by 16922.9% in 2022 and then skyrocketed by 1528.16% in 2023.
  • Celldex Therapeutics' EBT (Quarter) stood at -$20.1 million in 2021, then plummeted by 31.46% to -$26.5 million in 2022, then crashed by 63.5% to -$43.3 million in 2023, then dropped by 8.74% to -$47.1 million in 2024, then plummeted by 42.37% to -$67.0 million in 2025.
  • Its last three reported values are -$67.0 million in Q3 2025, -$56.6 million for Q2 2025, and -$53.8 million during Q1 2025.